| | | 广州万孚生物技术股份有限公司 关于召开 2023 年第一次临时股东大会的通知 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚 假记载、误导性陈述或者重大遗漏。 广州万孚生物技术股份有限公司（以下简称"公司"）于 2023 年 8 月 19 日召 开的第四届董事会第二十三次会议审议通过了《关于提请召开 2023 年第一次临 时股东大会的议案》，决定于 2023 年 8 月 31 日（星期四）召开公司 2023 年第一 次临时股东大会，现将本次股东大会的有关事项通知如下： 一、召开会议的基本情况 1、股东大会届次：2023 年第一次临时股东大会。 2、会议召集人：公司董事会。 3、会议召开的合规性：本次股东大会的召开符合有关法律、行政法规、部 门规章、规范性文件和《广州万孚生物技术股份有限公司章程》的有关规定，公 司第四届董事会第二十三次会议已经审议通过召开本次股东大会的议案。 4、会议召开的日期、时间： （1）现场会议召开时间为：2023 年 8 月 31 日（星期四）14:00。 （2）网络投票时间为：2023 年 8 月 31 日 9:15 至 2023 年 8 月 31 日 ...

Financial Performance - The company's revenue for Q1 2023 was ¥831,629,122.23, a decrease of 68.32% compared to ¥2,625,283,985.42 in the same period last year[7] - Net profit attributable to shareholders was ¥203,678,161.27, down 77.46% from ¥903,506,781.16 year-on-year[7] - Basic and diluted earnings per share were both ¥0.46, a decline of 77.56% from ¥2.05 in the same period last year[7] - Total operating revenue for Q1 2023 was CNY 831,629,122.23, a decrease of 68.3% compared to CNY 2,625,283,985.42 in the same period last year[26] - Net profit for Q1 2023 was CNY 202,212,680.82, a decrease of 77.7% compared to CNY 901,709,729.58 in Q1 2022[29] - The total comprehensive income for Q1 2023 was CNY 202,604,008.04, significantly lower than CNY 903,678,461.03 in Q1 2022, highlighting the impact of reduced profitability[32] Cash Flow - The net cash flow from operating activities improved by 37.98%, reaching -¥221,701,390.44 compared to -¥357,477,956.88 in the previous year[7] - The net cash flow from operating activities was -221,701,390.44 CNY, an improvement from -357,477,956.88 CNY in the previous period, indicating a 38% reduction in cash outflow[37] - Total cash inflow from operating activities was 707,399,227.91 CNY, down 41.3% from 1,203,610,658.01 CNY in the previous period[37] - Cash outflow from operating activities totaled 929,100,618.35 CNY, a decrease of 40.5% compared to 1,561,088,614.89 CNY last year[37] - The net cash flow from investing activities was 11,894,625.62 CNY, a significant recovery from -252,852,743.65 CNY in the previous period[37] - Cash inflow from investing activities was 1,120,787,819.86 CNY, down 35.9% from 1,747,447,477.63 CNY in the previous period[37] - Cash outflow from investing activities was 1,108,893,194.24 CNY, a decrease of 44.7% compared to 2,000,300,221.28 CNY last year[37] - The net cash flow from financing activities was -200,348,519.87 CNY, compared to a positive cash flow of 199,910,395.91 CNY in the previous period[37] - The total cash and cash equivalents at the end of the period were 748,525,744.53 CNY, an increase from 584,944,076.03 CNY in the previous period[39] Assets and Liabilities - Total assets at the end of the reporting period were ¥5,917,755,800.57, a decrease of 6.08% from ¥6,301,138,498.06 at the end of the previous year[7] - The company's total liabilities as of Q1 2023 amounted to CNY 1,171,298,113.68, compared to CNY 1,763,580,723.22 in the previous year[28] - Total current assets decreased from CNY 3,350,388,699.00 to CNY 3,214,883,420.68, indicating a decline of approximately 4.05%[23] - Total non-current assets decreased from CNY 2,950,749,799.06 to CNY 2,702,872,379.89, reflecting a decline of about 8.38%[23] - The total assets of the company decreased from CNY 6,301,138,498.06 to CNY 5,917,755,800.57, a reduction of approximately 6.09%[23] - Short-term borrowings significantly decreased from CNY 204,357,852.72 to CNY 3,000,000.00, a decline of about 98.53%[23] Shareholder Information - Total number of common shareholders at the end of the reporting period is 66,785, with the top ten shareholders holding a combined 33.17% of the total share capital[18] - The number of shares held by the top shareholder, Li Wenmei, is 97,843,968, representing 22.01% of the total shares[18] - The company's equity attributable to shareholders increased by 4.84% to ¥4,554,120,777.67 from ¥4,343,755,389.17 at the end of the previous year[7] - The total equity attributable to shareholders of the parent company increased to CNY 4,554,120,777.67 from CNY 4,343,755,389.17 year-on-year[28] Expenses and Income - The company reported a significant decrease in sales revenue primarily due to a reduction in antigen sales[13] - The company experienced a 58.21% reduction in selling expenses, amounting to ¥146,021,066.07 compared to ¥349,408,282.77 in the previous year[13] - Total operating costs for Q1 2023 were CNY 608,061,116.29, down from CNY 1,500,079,621.40 in the previous year, reflecting a significant reduction in expenses[29] - Research and development expenses for Q1 2023 were CNY 94,403,973.82, down from CNY 118,277,455.31 in the previous year, indicating a focus on cost management[29] - The company reported a decrease in sales expenses to CNY 146,021,066.07 from CNY 349,408,282.77 year-on-year, reflecting improved operational efficiency[29] - The company recorded other income of CNY 8,703,414.00 in Q1 2023, compared to CNY 2,095,331.29 in the same period last year, indicating potential growth in ancillary revenue streams[29] - Interest income increased by 224.51% to ¥2,529,282.86, up from ¥779,407.79 year-on-year[13] - The company received government subsidies amounting to ¥9,349,383.14, contributing positively to its financial performance[8] Inventory and Receivables - The company's inventory increased from CNY 399,967,713.19 to CNY 466,705,476.95, representing an increase of approximately 16.67%[23] - The total receivables increased from CNY 540,161,426.51 to CNY 564,452,271.95, indicating a growth of about 4.67%[23] - The company reported a total of 1,283,682,046.63 in trading financial assets at the end of the reporting period, up from CNY 938,071,800.35 at the beginning of the year[23]

证券代码：300482 证券简称：万孚生物 债券代码：123064 债券简称：万孚转债 广州万孚生物技术股份有限公司投资者关系活动记录表 | 投 资 者 关 系活动 | □特定对象调研 □分析师会议 | | --- | --- | | 类别 | □媒体采访□业绩说明会 | | | □新闻发布会 □路演活动 | | | □现场参观 | | | √其他：电话会议，投资者线上交流会 | | 参 与 单 位 名称及 | 广发证券股份有限公司、海通证券股份有限公司、华创证券股份有限公司等 | | 人员姓名 | | | 时间 | 2023 年 3 月 31 日 | | 地点 | 电话会议 | | 上 市 公 司 接待人 | 董事长：王继华 | | 员姓名 | 董事会秘书：胡洪 | | | 财务总监：余芳霞 | | | 证券事务代表：华俊 | | | 一、2022 年全年经营情况介绍： | | | 2022 年，对万孚生物来说，是成立三十周年的而立之年，也是继往开来、 | | | 承前启后的一年。报告期内，公司实现营业收入 56.8 亿元，比上年同期增长 | | | 69%；归属于上市公司股东的净利润 11.97 亿元，比 ...

Financial Performance - The company's operating revenue for 2022 reached ¥5,680,513,174.77, representing a 69.01% increase compared to ¥3,361,043,277.33 in 2021[25]. - Net profit attributable to shareholders for 2022 was ¥1,196,968,338.20, an increase of 88.67% from ¥634,433,145.20 in the previous year[25]. - The net profit after deducting non-recurring gains and losses was ¥1,105,006,709.65, up 100.70% from ¥550,583,020.43 in 2021[25]. - Cash flow from operating activities for 2022 was ¥1,682,171,310.01, a significant increase of 152.98% compared to ¥664,930,290.53 in 2021[25]. - Basic earnings per share for 2022 were ¥2.71, reflecting an increase of 89.51% from ¥1.43 in 2021[25]. - Total assets at the end of 2022 amounted to ¥6,301,138,498.06, a 29.76% increase from ¥4,855,824,467.37 at the end of 2021[25]. - The net assets attributable to shareholders at the end of 2022 were ¥4,343,755,389.17, up 29.54% from ¥3,353,100,618.30 in 2021[25]. - The company's non-operating income totaled ¥91,961,628.55 in 2022, an increase of 9.5% from ¥83,850,124.77 in 2021[31]. - The fair value changes and investment income from trading financial assets reached ¥69,780,497.57, up from ¥53,555,315.92 in 2021, indicating a significant increase of 30.4%[31]. Market Presence and Expansion - In 2022, the company's overseas revenue accounted for 49.43% of total operating income, indicating significant reliance on international markets[8]. - The company has established nine major technology platforms, covering various diagnostic fields, and products are sold in over 140 countries and regions[5]. - The company has expanded its international market presence since 2004, adhering to quality control standards from developed countries[55]. - The company operates a dual sales model, primarily using distribution in China and focusing on direct sales for self-testing products through e-commerce platforms[46][48]. - The international market contributes significantly to revenue, with the immunofluorescence and immunochromatography platforms being the main revenue drivers, and a noticeable increase in the proportion of quantitative products[52]. - The company is actively pursuing international market expansion with a structured approach to improve operational capabilities in key overseas regions[153]. - The company is establishing local operations in key countries to enhance service quality and support for small laboratories abroad[154]. Product Development and Innovation - The company has a diversified product line in the POCT industry, focusing on cardiovascular diseases, infections, and drug abuse testing[5]. - The company is continuously innovating its product pipeline, focusing on chronic diseases and common illnesses to enhance competitiveness[67]. - The company developed 111 new products during the reporting period, including 31 on the colloidal gold platform and 44 on the immunofluorescence platform[98]. - The company’s new COVID-19 antigen test received WHO EUL certification, enhancing its market potential[84]. - The company’s HIV self-test product obtained WHO PQ certification, aiming to improve global HIV testing coverage[103]. - The company is expanding its product lines in chemical luminescence, molecular diagnostics, and pathology diagnostics, focusing on critical and chronic diseases[151]. Regulatory and Compliance - The company emphasizes compliance with international quality standards, having received multiple certifications from FDA and CE[6]. - The company has received IVDR certification, enhancing its competitive advantage in the European market, but ongoing R&D capabilities are crucial for future growth[5]. - The company obtained the TÜV:SÜD certification for the MDSAP quality management system, confirming compliance with regulations from the USA, Canada, Brazil, and Australia[56]. - The company’s quality management system met all regulatory requirements, with 34 audits and 16 self-inspections conducted during the reporting period[102]. Risks and Challenges - The company faces risks related to new product development, registration, and certification due to stricter regulatory policies in China, the EU, and the US[5]. - The implementation of the "two-invoice system" in some regions may impact the company's distribution network and sales performance[8]. - Currency fluctuations may affect the company's financial performance due to its substantial foreign sales[8]. - The company has experienced rapid business expansion, which may lead to quality control risks if risk management does not keep pace[6]. Governance and Management - The company has held three shareholder meetings during the reporting period, reviewing 29 proposals to ensure compliance with governance standards[158]. - The board of directors consists of seven members, including three independent directors, ensuring compliance with relevant laws and enhancing decision-making capabilities[159]. - The company has a diverse management team with members holding various academic qualifications, including medical and financial degrees[173][174]. - The company has established performance evaluation standards and incentive mechanisms for senior management, ensuring transparency in appointments[162]. - The company maintains independent operations in terms of assets, personnel, finance, and business, complying with relevant laws and regulations[163]. Research and Development - The company invested 446.85 million yuan in R&D, accounting for 7.87% of total revenue[92]. - The company's R&D investment amounted to ¥446,853,040.79 in 2022, representing 7.87% of total revenue, a decrease from 13.66% in 2021[121]. - The number of R&D personnel decreased by 3.13% to 805 in 2022, with a notable drop in master's degree holders by 11.33%[121]. - The company has been actively involved in research and development, with its general manager overseeing product and operational centers[169]. Strategic Initiatives - The company emphasizes strategic collaboration and market expansion through both organic growth and acquisitions to maintain a competitive edge[45]. - The company has formed a strategic layout of an "ecological circle," expanding its business through mergers and strategic partnerships[75][76]. - The company follows a "dual circulation" development strategy, focusing on both domestic and international markets to promote balanced and rapid growth[149]. - The company emphasizes a dual-core business system of B2B and B2C, with a focus on innovation-driven and scenario-oriented product strategies[149]. Shareholder Engagement - The company plans to distribute a cash dividend of 5 RMB per 10 shares (including tax) to all shareholders as part of its profit distribution plan for 2022[9]. - The first temporary shareholders' meeting in 2022 had a participation rate of 50.69%[165]. - The annual shareholders' meeting in 2021 had a participation rate of 48.36%[165]. - The second temporary shareholders' meeting in 2022 had a participation rate of 35.79%[165].

关于举办2022年度业绩网上说明会的公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚 假记载、误导性陈述或重大遗漏。 广州万孚生物技术股份有限公司（以下简称"公司"）《2022 年年度报告》 及其摘要于 2023 年 3 月 31 日刊登在中国证监会指定的创业板信息披露网站巨潮 资讯网（http://www.cninfo.com.cn）、《证券时报》、《中国证券报》、《证 券日报》和《上海证券报》。 | 证券代码：300482 | 证券简称：万孚生物 公告编号：2023-023 | | --- | --- | | 债券代码：123064 | 债券简称：万孚转债 | 为了让广大投资者进一步了解公司 2022 年年度经营情况，公司将于 2023 年 3 月 31 日（星期五）15:00-17:00 在深圳证券信息有限公司提供的网上平台举行 2022 年度业绩网上说明会。本次说明会将采用网络远程方式举行，投资者可登陆 "全景•路演天下"（http://rs.p5w.net）参与本次业绩说明会。 出席本次业绩说明会的人员有：公司董事长王继华女士，独立董事陈锦棋先 生，董事会秘书胡洪女士，财务负责 ...

证券代码：万孚生物 证券简称：300482 编号： 1 广州万孚生物技术股份有限公司投资者关系活动记录表 | --- | --- | --- | |----------------------|------------|-------------------------------------------------------------------------------------------------------------------------| | | | | | 投 资 者 关 系 活 动 | □ | 特定对象调研 □分析师会议 | | 类别 | □ | 媒体采访 □业绩说明会 | | | □ | 新闻发布会 □路演活动 | | | □ 现场参观 | | | | □ | 其他 （请文字说明其他活动内容） | | 参 与 单 位 名 称 及 | | 联讯证券、竣弘投资、东方资本、银石投资、融捷投资、银河证券、玖哥投 | | 人员姓名 | | 资、中航证券、亚宝投资、前海旗隆、冠丰资产、前海皇庭资本、长城证 券、厚生和投资、粤信金融、鹿峰投资。 | | 时间 | 2015-11-18 | | | ...

Group 1: Market Overview - The company has a high proportion of overseas market presence, with a focus on expanding quantitative products domestically [2] - New product registration in foreign markets takes longer, but sales increase significantly post-registration [2] - The largest market for similar products abroad is Europe, with a focus on OEM brands in large chain supermarkets [3] Group 2: Product and Sales Channels - The pregnancy testing market is primarily through supermarkets, with a growing emphasis on e-commerce platforms [3] - The company has a stable distribution network with no significant additional costs, mainly focusing on e-commerce expenses [3] - Infectious disease products are primarily self-branded, with some OEM for drugs and pregnancy tests [4] Group 3: Future Growth and Development - The company anticipates growth in drug testing markets outside of China and the U.S., with new testing varieties expected [4] - The market for chronic disease products is primarily quantitative, with significant sales potential in community healthcare settings [4] - The sales team has increased by approximately 10-20% domestically, with a larger demand in Europe and the U.S. [4] Group 4: New Product Development - The company plans to launch new platforms, including dry chemistry and microfluidics, in addition to existing qualitative and quantitative platforms [5] - Investments have been made in portable ECG devices as part of health management preparations [5]

Group 1: Company Overview - Guangzhou Wanfu Biological Technology Co., Ltd. offers qualitative and quantitative products, with pregnancy detection products being a notable example of qualitative products available in retail [2] - The company has been developing quantitative products for over five years, which provide specific numerical results and require machines for use [3] - The IVD market is growing annually, with Wanfu Biological maintaining a strong position and investing approximately 10% of sales revenue in R&D each year [3] Group 2: Market Performance - The quantitative products have seen over 30% annual growth in recent years, with higher gross margins compared to qualitative products [3] - Domestic sales accounted for approximately 60% of total sales in 2014, with a trend of increasing domestic sales and decreasing international sales [3] - The company expects domestic business to maintain around 20% annual growth, outpacing international market growth [4] Group 3: Competitive Landscape - Wanfu Biological differentiates itself from competitors like Meikang and Dirui by focusing on POCT (Point of Care Testing) and having a significant international sales presence [4] - The company’s main market includes secondary and tertiary hospitals, as well as community hospitals [4] Group 4: Product Development and Sales Strategy - The company plans to launch approximately 10 new products annually, focusing on extending existing product lines rather than diversifying into new areas [3] - Future quantitative products are expected to be launched in Europe and Asia, with heart attack-related products anticipated to be among the first [4] - The company is enhancing its international sales team to improve sales of quantitative products abroad, which require specialized knowledge for effective marketing and support [4][5] Group 5: Financial Outlook - The company’s performance is expected to remain stable, with no significant seasonal fluctuations in orders [5] - The depreciation of the RMB is beneficial for the company due to its substantial export share, which is projected to contribute positively to financial results [4]

证券代码：万孚生物 证券简称：300482 编号： 广州万孚生物技术股份有限公司投资者关系活动记录表 | --- | --- | --- | |----------------------|-------------------------|-------------------------------------------------------------------------------------------------------------------------| | | | | | 投 资 者 关 系 活 动 | □ | 特定对象调研 □分析师会议 | | 类别 | □ | 媒体采访 □业绩说明会 | | | □ 新闻发布会 □路演活动 | | | | □ 现场参观 | | | | □ | 其他 （请文字说明其他活动内容） | | 参 与 单 位 名 称 及 | | 博时基金、中金蓝海资管、西南证券、民生银行、安信证券、尊道投资、尚 | | 人员姓名 | | 道投资、乐信资管、瑞天投资、通晟资产、广州证券、冠丰资产、广发资产 管理、中科沃土基金、华创证券、。 | | 时间 | 2016-5 ...

Group 1: Company Strategy and Market Position - The company focuses on three main areas: cardiovascular diseases, respiratory diseases, and infectious diseases, with the reproductive health sector being of lower strategic importance due to its limited market capacity [2]. - The company has been promoting its reproductive health products through e-commerce and various distributors, indicating future growth potential in this sector [2]. Group 2: Financial Performance and Growth - The company maintained a net profit growth rate of over 20% in the current year, despite a slowdown in growth over the past two years [3]. - The company invests over 10% of its revenue in research and development annually [3]. Group 3: Product Development and Innovation - The company has the only domestic product for sperm motility testing, which provides a competitive edge over other POCT industry companies [3]. - New products are expected to be launched annually, with a three-year planning cycle for product development [3]. Group 4: Sales and Marketing Strategy - The sales model is based on a distributor approach, with a goal of globalizing the business across R&D, production, and sales [4]. - Recent CE certifications for products related to myocardial infarction and heart failure are expected to enhance sales in Europe and the United States [4]. Group 5: Mergers and Acquisitions - The company aims to pursue technology-driven mergers and acquisitions to enhance its product line and production capabilities [4]. - The company has a stable history of operations and plans to maintain a cautious approach in investment activities [4]. Group 6: Government Support and Financial Impact - Government subsidies have remained stable at around 20 million, primarily supporting high-tech enterprises and biopharmaceutical research [4]. - As the company grows, the proportion of government subsidies to net profit is expected to decrease, indicating a reduced reliance on such support [4].